You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

Drug Sales Trends for IRBESARTAN


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for IRBESARTAN (2022)

Revenues by Pharmacy Type

Pharmacy Type Revenues
MAIL-ORDER $25,028,941
INSIDE ANOTHER STORE $15,684,800
[disabled in preview] $91,367,896
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
MAIL-ORDER 476,184
INSIDE ANOTHER STORE 459,262
[disabled in preview] 1,052,897
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $1,274,314
MEDICARE $82,012,646
[disabled in preview] $48,794,676
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for IRBESARTAN
Drug Units Sold Trends for IRBESARTAN

Annual Sales Revenues and Units Sold for IRBESARTAN

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
IRBESARTAN ⤷  Try for Free ⤷  Try for Free 2022
IRBESARTAN ⤷  Try for Free ⤷  Try for Free 2021
IRBESARTAN ⤷  Try for Free ⤷  Try for Free 2020
IRBESARTAN ⤷  Try for Free ⤷  Try for Free 2019
IRBESARTAN ⤷  Try for Free ⤷  Try for Free 2018
>Drug Name >Revenues (USD) >Units >Year

Global Irbesartan Market Analysis and Sales Projections

Last updated: December 31, 2024

Introduction to Irbesartan

Irbesartan is an angiotensin II receptor antagonist, widely prescribed for the management of hypertension and related cardiovascular diseases. It is also used to treat kidney problems caused by type 2 diabetes. The global market for Irbesartan tablets is experiencing significant growth, driven by several key factors.

Market Size and Forecast

The global Irbesartan Tablets market was valued at USD 3.10 billion in 2023 and is projected to reach USD 3.85 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 2.45% from 2024 to 2030[2].

Another projection indicates that the Irbesartan Market size was valued at USD 2.04 billion in 2023 and is expected to reach USD 2.87 billion by 2031, growing at a CAGR of 11.95% from 2024 to 2031[5].

Key Drivers of the Market

Increasing Prevalence of Hypertension

The global burden of hypertension is increasing, affecting an estimated 26% of the world’s population, with this figure expected to rise to 29% by 2025. This rising prevalence is a major driver for the demand of Irbesartan tablets[2].

Rising Geriatric Population

The aging population is more susceptible to hypertension, which drives the demand for Irbesartan tablets as a therapeutic option for blood pressure management. The geriatric population's increasing need for hypertension management solutions is a significant market driver[1].

Lifestyle Changes and Urbanization

Sedentary lifestyles, unhealthy dietary habits, and urbanization are contributing to the rising prevalence of hypertension, creating a substantial market opportunity for Irbesartan tablets[1].

Market Segmentation

By Product Type

The market is segmented into 75 mg, 150 mg, and 300 mg tablets. The 150 mg tablets are often more effective at controlling blood pressure for 24 hours compared to the 75 mg dose, although the latter may be recommended for certain patient groups, such as hemodialysis patients and those over 75 years old[2].

By Distribution Channel

The market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies are expected to grow at a significant rate during the forecasted years due to the high volume of prescriptions filled in these settings[2].

By Geography

The global Irbesartan Tablets market is classified into North America, Europe, Asia-Pacific, and the Rest of the world. North America currently holds the largest market share, driven by a high prevalence of hypertension and well-established healthcare infrastructure. However, the Asia-Pacific region is expected to witness significant growth due to the increasing geriatric population, improving access to healthcare, and rising awareness about hypertension management[1][2].

Competitive Landscape

The global Irbesartan Tablets market is highly competitive, with several pharmaceutical manufacturers operating at global and regional levels. Key players include Pfizer Inc., AstraZeneca PLC, Sanofi S.A., Novartis International AG, Teva Pharmaceutical Industries Ltd., Apotex, Jiangsu Hengrui Medicine, Taj Pharmaceuticals, and Zhuhai Rundu Pharmaceutica. These companies focus on product development, strategic alliances, and marketing initiatives to maintain their market position and gain a competitive advantage[1][2].

Market Trends

Personalized Treatment Approaches

The trend towards personalized medicine and tailored treatment approaches provides opportunities for customized Irbesartan dosing regimens and combination therapies. This personalized approach can enhance patient outcomes and improve the efficacy of hypertension management[1].

Focus on Patient-Centric Care

Healthcare providers are increasingly emphasizing patient-centric care, which includes individualized hypertension management plans incorporating Irbesartan tablets. This focus on patient-centric care is expected to drive the market forward by improving patient compliance and outcomes[1].

Impact of COVID-19

The COVID-19 pandemic has had a mixed impact on the Irbesartan Tablets market. On one hand, it has raised awareness about the importance of maintaining good health and managing underlying conditions such as hypertension. On the other hand, disruptions in healthcare services and supply chains have affected the market dynamics and patient access to medications[1].

SWOT Analysis

Strengths

  • Irbesartan tablets are a proven and widely prescribed medication for hypertension management, offering efficacy in blood pressure control and reducing the risk of cardiovascular diseases[1].

Weaknesses

  • Irbesartan tablets can have potential side effects and adverse reactions, which may impact patient compliance. The presence of generic versions in the market may also affect market share and pricing[1].

Opportunities

  • The growing emphasis on preventive healthcare, emerging markets, and technological advancements present opportunities for market expansion and the development of innovative formulations[1].

Threats

  • Competition from alternative antihypertensive medications and the stringent regulatory landscape pose threats to the market growth and profitability[1].

Key Industry Developments

The global Irbesartan Tablets market is expected to witness steady growth in the coming years, driven by the increasing prevalence of hypertension and the growing awareness of blood pressure management. Technological advancements, personalized treatment approaches, and collaborations are expected to shape the future of the market. However, challenges such as generic competition and stringent regulatory requirements need to be addressed for sustained market growth[1].

Contribution to Public Health

The availability of Irbesartan tablets contributes to public health initiatives by addressing the global burden of hypertension and promoting awareness about blood pressure management. Effective management of hypertension reduces the risk of cardiovascular diseases and improves overall health outcomes[1].

"Hypertension affects an estimated 26% of the world’s population, and the prevalence is expected to rise to 29% by 2025, owing mostly to increases in economically developing countries"[2].

Market Growth and Revenue Opportunities

The growing prevalence of hypertension and the increasing demand for Irbesartan tablets offer revenue opportunities for pharmaceutical manufacturers and stakeholders in the healthcare industry. The market is expected to grow steadily, driven by the need for effective blood pressure management solutions[1].

Key Takeaways

  • The global Irbesartan Tablets market is driven by the increasing prevalence of hypertension and the growing demand for effective blood pressure management solutions.
  • The market is segmented by product type, distribution channel, and geography, with North America holding the largest market share but the Asia-Pacific region expected to witness significant growth.
  • Key players focus on product development, strategic alliances, and marketing initiatives to maintain their market position.
  • Personalized treatment approaches and patient-centric care are emerging trends in the market.
  • The COVID-19 pandemic has had a mixed impact on the market, raising awareness but also causing disruptions in healthcare services and supply chains.

FAQs

1. What is the current market size of the Irbesartan Tablets market?

The global Irbesartan Tablets market was valued at USD 3.10 billion in 2023[2].

2. What is the projected growth rate of the Irbesartan Tablets market?

The market is projected to grow at a CAGR of 2.45% from 2024 to 2030[2].

3. Which region holds the largest market share for Irbesartan Tablets?

North America currently holds the largest market share, driven by a high prevalence of hypertension and well-established healthcare infrastructure[1].

4. What are the key drivers of the Irbesartan Tablets market?

The key drivers include the increasing prevalence of hypertension, the rising geriatric population, and lifestyle changes leading to hypertension[1].

5. Who are the major players in the Irbesartan Tablets market?

Major players include Pfizer Inc., AstraZeneca PLC, Sanofi S.A., Novartis International AG, Teva Pharmaceutical Industries Ltd., Apotex, Jiangsu Hengrui Medicine, and others[1][2].

Sources

  1. MarkWide Research: Global Irbesartan Tablets market 2024-2032 | Size, Share, Growth[1].
  2. Verified Market Research: In-Depth Industry Outlook: Irbesartan Tablets Market Size & Forecast[2].
  3. Verified Market Reports: Irbesartan Market Size, Share And Growth | Report [2023-2030][3].
  4. Market Research Intellect: Irbesartan Market Size and Projections - Market Research Intellect[5].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.